(688192)"DIZAL PHARMACEUTICAL CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 688192 · · 13 pages · Chinese
Summary by 6ix AI
The report confirms that the financial data has not been audited and emphasizes the accuracy and completeness of the information provided. The report also outlines ongoing research and development efforts, including advancements in cancer treatment drugs.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Dizal (Jiangsu) Pharmaceutical Co. Ltd. on 6ix
Earlier from Dizal (Jiangsu) Pharmaceutical
- (688192)"DIZAL PHARMACEUTICAL CO., LTD."Indicative Announcement on Change in Equity Interests of Shareholder Holding More Than 5% of the Shares and Its Persons Acting in Concert Reaching an Integer Multiple of 5% Threshold and Disclosure of Simplified Report on Change in Equity Interests
- (688192)"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Receipt of a USD 600 Million Upfront Payment from AstraZeneca for the Global Licensing of ZEGFROVY
- Announcement on Use of Temporarily Idle Self-owned Funds for Entrusted Wealth Management
- Announcement on Shareholding Reduction Plan of Senior Executive
- Announcement on Voluntary Disclosure of Publication of Research Results on Birelentinib for the Treatment of Diffuse Large B-Cell Lymphoma in "Blood Cancer Journal"
Later from Dizal (Jiangsu) Pharmaceutical
All Dizal (Jiangsu) Pharmaceutical news releasesFollow Dizal (Jiangsu) Pharmaceutical into a list and get an email when it puts out news.
Follow Dizal (Jiangsu) Pharmaceutical